Navigation Links
New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
Date:8/20/2007

Mark S. George, M.D. Named Editor-in-Chief of New Brain Stimulation Journal

CHARLESTON, S.C., Aug. 20 /PRNewswire/ -- Medical University of South Carolina (MUSC) today announced the results of a functional MRI (fMRI) study examining the effects of VNS (Vagus Nerve Stimulation) Therapy(TM) for patients with treatment-resistant depression (TRD). The study, led by Ziad Nahas, M.D., associate professor, MUSC Department of Psychiatry, appears in the August 2007 issue of peer-reviewed Neuropsychopharmacology. The results show that VNS Therapy modulates areas of the brain that control mood. The researchers also identified variables, such as length of use, strength of stimulation and level of depression, to better understand the impact of VNS Therapy.

"These data provide further insight into VNS therapy's distinct mechanism of action and support its previously demonstrated long-term, sustained efficacy," Nahas said. "We are encouraged to see the unique benefit VNS therapy may bring to patients with one of the most difficult-to-treat forms of depression and are excited to continue neurostimulation research at MUSC."

The study illustrates that VNS Therapy modifies activity of the medial prefrontal cortex, the same area of the brain targeted by many antidepressant medications and electroconvulsive therapy (ECT). A critical time for such effective modulation occurs approximately at 30 weeks of treatment. Such modulation could support VNS Therapy's unique mechanism of action as a long- term treatment for chronic or recurrent depression and directly corresponds with the timeframe in which patients typically experience a decrease in symptoms. Further analysis of the data demonstrates that modulation of the brain is a dynamic process that over time leads to indirectly related improved response with continued use. These findings corroborate an earlier MUSC-led study that revealed approximately two-thirds of patients who respond to VNS Therapy continue to experience significant clinical benefit at 24 months, making VNS Therapy the only treatment for TRD to demonstrate such long-term improvements.

The FDA approved VNS therapy in 2005 as an adjunctive long-term treatment of chronic or recurrent depression for patients (18 years of age or older) who are experiencing a major depressive episode and have not had an adequate response to four or more antidepressant treatments. It is the only device ever studied and approved for treatment-resistant depression. VNS therapy is delivered from a small pacemaker-like device implanted in the chest area that sends mild pulses to the brain via the vagus nerve in the neck.

Nahas' esteemed colleague Mark S. George, M.D., MUSC Departments of Psychiatry, Neurology and Radiology, shares this vision and supports the need for additional research to maximize the potential of neurostimulation as a diagnostic and therapeutic agent. George has launched a new international, peer-reviewed journal that is dedicated to exploring the field of neuromodulation. Published by Elsevier, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation strives to provide the most comprehensive collection of research being conducted in this emerging field. As editor-in-chief, George's extensive experience researching neurostimulation applications will aide him in facilitating and shaping the field's promising future.

About MUSC

Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the south. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC is home to over 3,000 students and residents, as well as nearly 10,000 employees, including 1,300 faculty members. As the largest non-federal employer in Charleston, the University and its affiliates have collective budgets in excess of $1.3 billion per year. MUSC operates a 600 bed medical center, which includes a nationally recognized Children's Hospital and a leading Institute of Psychiatry. For more information on academic information or clinical services visit http://www.musc.edu or http://www.muschealth.com.


'/>"/>
SOURCE Medical University of South Carolina

Copyright©2007 PR Newswire.

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel ... Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety of ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
Breaking Medicine News(10 mins):